Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scalop Trial Logo

The first patient has now been randomised to the SCALOP-2 trial, a multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer.

Similar stories

SITU announces a trio of new trials

SITU-NDORMS has announced the launch of three major new clinical trials. Funded by the NIHR, these studies are providing evidence for the treatment of chronic low back pain, knee osteoarthritis, and ACL injuries.